Abstract
Advanced renal cell carcinoma is relatively resistant to most adequately evaluated chemotherapeutic agents. The combination of CCNU and vinblastine, which has antitumor activity in a frog renal carcinoma model system, has demonstrated activity in initial studies in man. The current study investigated this combination of drugs together with a progestational agent, Delalutin. Seventeen patients with metastatic renal cell carcinoma were treated with CCNU, vinblastine and Delalutin. There were no objective responses. Four patients with stable disease had a mean survival of 18 months compared to 13 patients with progressive disease who had a mean survival of 5 months. The survival of the four patients with stable disease was in large part due to the slowly progressive natural history of their disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 89-91 |
| Number of pages | 3 |
| Journal | Medical and Pediatric Oncology |
| Volume | 5 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1978 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- CCNU
- Delalutin
- chemotherapy
- hypernephroma
- vinblastine
Fingerprint
Dive into the research topics of 'CCNU, vinblastine, and delalutin therapy in renal cell carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS